Table IV.
Comparison of the prevalence of associated diseases and abnormalities in women with (NAFLD+) or without NAFLD (NAFLD-)
| Variable | NAFLD+ ( n=198 ） | NAFLD- (n=404 ） | p-value |
|---|---|---|---|
| IR (n=368) | 187 (94.4%) | 181 (44.8%) | <0.001* |
| Abdominal obesity (n=245) | 156 (78.8%) | 89 (22.0%) | <0.001* |
| Diabetes mellitus (n=33) | 28 (14.1%) | 5 (1.2%) | <0.001* |
| Abnormal glucose tolerance (n=89) | 56 (28.3%) | 33 (8.2%) | <0.001* |
| Liver dysfunction (n=86) | 56 (28.3%) | 30 (7.4%) | <0.001* |
| Dyslipidemia (n=146) | 84 (42.4%) | 62 (15.3%) | <0.001* |
| Hypertension (n=29) | 21 (10.1%) | 8 (2.0%) | <0.001* |
| Metabolic syndrome (n=177) | 163 (82.3%) | 14 (3.5%) | <0.001* |
NAFLD: non-alcoholic fatty liver disease; IR: insulin resistance.
Metabolic syndrome refers to the standard revised at the 2003 Rotterdam conference (The Rotterdam ESHRE/ASRM -Sponsored PCOS Work shop Group, 2004a).
Analysis were performed with the Chi-square test. A p-value of <0.01 was considered statistically significant.
*
Compared with NAFLD- group.